Celgene Corp: (NASD: CELG)
$124.91
1.43 (1.16%)
Volume 4,118,134
May 17 04:00 PM ET
Zacks Rank: 2-Buy 
| #2 |
Overview Quote
Stock Activity
| Day Low - High | 120.35 - 125.05 |
| 52wk Low - High | 58.53 - 131.82 |
| Previous Close | 123.48 |
| Avg. Volume | 3,572,611 |
| Industry | MED-BIOMED/GENE |
| Market Cap | 52.31 B |
| Div - Yield | 0.00 - 0.00 |
| Beta | 0.67 |
| PE (Forward) | 23.98 |
| Current Year Est. | 5.21 |
| Quarterly Earnings ESP |
0.00% |
Premium research
Zacks Rank
|
2 |
Zacks Recommendation
|
Neutral |
Zacks Industry Rank
|
91 out of 265 |
Equity Research Report
|
PREMIUM |
( = Change in last 30 days)
Get all our stock ratings and recommendations with a Free Trial to Zacks Premium Start Free Trial
Key Earnings Data
| PE (Forward) | 23.98 |
| PEG Ratio | 0.98 |
| Current Year Est. | 5.21 |
| Current Quarter Estimate | 1.31 |
| Most Accurate Estimate | 1.31 |
| Earnings ESP |
0.00% |
| Next Earnings Report Date | 07-25-2013 |
| EPS Last Year | 4.77 |
| Expected Earnings Growth | 24.49% |
Company Description
Celgene Corp. is an independent biopharmaceutical company engaged primarily in the discovery, development and commercialization of orally administered, small molecule drugs for the treatment of cancer and immunological diseases.
NYSE data is at least 20 minutes delayed.
NASDAQ data is at least 15 minutes delayed.
Turn Earnings Surprises into quick profits.
Earnings Estimates
| Current Qtr (06/2013) |
Next Qtr (09/2013) |
Current Year (12/2013) |
Next Year (12/2014) |
|
|---|---|---|---|---|
| Average Estimate | 1.31 | 1.29 | 5.21 | 6.36 |
| Number of Estimates | 4 | 4 | 4 | 4 |
| Low Estimate | 1.25 | 1.26 | 5.08 | 5.91 |
| High Estimate | 1.36 | 1.37 | 5.46 | NA |
| Year Ago EPS | 1.12 | 1.19 | 4.50 | 5.21 |
| EPS Growth | 16.74% | 8.61% | 15.78% | 22.12% |
Industry Analysis
| Name | Symbol | Previous Close | Zacks Rank | Zacks Recommendation |
|---|---|---|---|---|
| CELGENE CORP | CELG | 124.91 | |
|
| AETERNA ZENTARS | AEZS | 2.10 | |
|
| ANIKA THERAPEUT | ANIK | 14.40 | |
|
| GENTIUM SPA-ADR | GENT | 8.87 | |
|
| AASTROM BIOSCI | ASTM | 0.57 | |
|
| ACHILLION PHARM | ACHN | 7.77 | |
|
| ADDEX THERA LTD | ADDXF | 6.94 | |
|
| AFFYMAX INC | AFFY | 1.33 | |
|
| ALEXION PHARMA | ALXN | 102.90 | |
|
| ALKERMES INC | ALKS | 31.69 | |
|
Sector:Medical>> Industry:MED-BIOMED/GENE
COMPARE TICKER vs. Its Peers
Zacks Commentary
Myriad Soars Higher on Celeb Clout
May 15, 2013
Wider-Than-Expected Loss at Athersys
May 15, 2013
Celgene Attains 52-Week High
May 14, 2013
NPS Pharma Incurs Narrower 1Q Loss
May 14, 2013
Setback for Endo Health on Opana ER
May 13, 2013
Genomic Gains Coverage for DCIS
May 13, 2013
Earnings Beat at Warner Chilcott
May 13, 2013
Positive Data on Celgene's Apremilast
May 09, 2013
Financials
| EPS TTM | 4.77 |
| Sales | 5,507 |
| Net Income | 1,440 |
| Price/Earnings | 26.19 |
| Price/Book | 9.42 |
| Price/Cash Flow | 23.32 |
| Price/Sales | 9.18 |
News
WEALTHMAKERS.COM Issues Bullish Research Reports on ACIW, AEZS, ARCO, BODY, CELG, CLD - M2
May 17, 2013
3 Companies That Put the "Tech" in "Biotech" - TheMotleyFool
May 16, 2013
Gilead Drug For Leukemia Shows Success In Early Trial - Investors Business Daily
May 16, 2013
Stocks Close Lower; Dell Little Changed After Earnings - Investors Business Daily
May 16, 2013
Stocks Fade Late On Data, Fed - Investors Business Daily
May 16, 2013
Stocks Flat In Late Trading, But Cisco Lifts Nasdaq - Investors Business Daily
May 16, 2013
Stocks Little Changed; Qihoo, Ocwen Hit New Highs - Investors Business Daily
May 16, 2013
Wall Street Turns Down At The Bell; Celgene Sells Off - Investors Business Daily
May 16, 2013
Broker Recommendations
| Current ABR | 1.36 |
| ABR (Last Week) | 1.37 |
| # of recs in ABR | 25 |
| Average Target Price | 128.30 |
| Industry Rank by ABR | 91 out of 265 |
| Rank in Industry | 4 out of 155 |
